A Transformative LDL Cholesterol–Lowering In Vivo CRISPR Gene Editing Medicine That Functionally Upregulates LDLR in Mice and Non-Human Primates

Mar

9

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Feb

23

Editas Medicine to Participate in Upcoming Investor Conferences

Nov

10

Editas Medicine Announces Third Quarter 2025 Results and Business Updates